A carregar...

Development and targeted use of nilotinib in chronic myeloid leukemia

The development of imatinib has resulted in sustained hematologic and cytogenetic remissions in all phases of chronic myeloid leukemia (CML). Despite the high efficacy, relapses have been observed and are much more prevalent in patients with advanced disease. The most common mechanism of acquired re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Fava, Carmen, Kantarjian, Hagop, Cortes, Jorge, Jabbour, Elias
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2009
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2761189/
https://ncbi.nlm.nih.gov/pubmed/19920910
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!